Novartis Hit By Canakinumab NSCLC Miss
Interleukin-1 Beta Inhibitor Fails To Improve Survival
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
